Brainstorm Cell Therapeutics Inc. (BCLI) Financial Statements (2024 and earlier)

Company Profile

Business Address 1325 AVENUE OF AMERICAS
NEW YORK, NY 10019
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments748,0002,227,0002,983,0007,393,00012,244,00018,397,000
Cash and cash equivalents546,0002,021,000772,0004,144,0009,005,00015,151,000
Short-term investments202,000206,0002,211,0003,249,0003,239,0003,246,000
Receivables93,00044,00091,00058,000117,00061,000
Prepaid expense    36,000  
Other undisclosed current assets372,000658,00032,00015,000445,000802,000
Total current assets:1,213,0002,929,0003,106,0007,502,00012,806,00019,260,000
Noncurrent Assets
Other noncurrent assets4,534,0004,943,0005,345,0005,752,0006,155,0006,531,000
Total noncurrent assets:4,534,0004,943,0005,345,0005,752,0006,155,0006,531,000
TOTAL ASSETS:5,747,0007,872,0008,451,00013,254,00018,961,00025,791,000
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities5,280,0007,973,0006,308,0006,453,0005,336,0004,641,000
Accounts payable5,190,0007,802,0006,224,0006,395,0005,292,0004,570,000
Accrued liabilities90,000171,00084,00058,00044,00071,000
Other undisclosed current liabilities2,411,0002,449,0002,492,0002,495,0002,510,0002,731,000
Total current liabilities:7,691,00010,422,0008,800,0008,948,0007,846,0007,372,000
Noncurrent Liabilities
Long-term debt and lease obligation:    2,918,0003,264,0003,932,000
Liabilities, other than long-term debt1,938,0002,290,0002,666,000   
Financial instruments subject to mandatory redemption, settlement terms, share value, amount      
Operating lease, liability1,938,0002,290,0002,666,0002,918,0003,264,0003,932,000
Other undisclosed noncurrent liabilities    (2,918,000)(3,264,000)(3,932,000)
Total noncurrent liabilities:1,938,0002,290,0002,666,0002,918,0003,264,0003,932,000
Total liabilities:9,629,00012,712,00011,466,00011,866,00011,110,00011,304,000
Equity
Equity, attributable to parent(3,882,000)(4,840,000)(3,015,000)1,388,0007,851,00014,487,000
Common stock12,00012,00012,00012,00012,00012,000
Treasury stock, value(116,000)(116,000)(116,000)(116,000)(116,000)(116,000)
Additional paid in capital204,431,000198,144,000194,910,000194,295,000193,900,000193,495,000
Accumulated deficit(208,209,000)(202,880,000)(197,821,000)(192,803,000)(185,945,000)(178,904,000)
Total equity:(3,882,000)(4,840,000)(3,015,000)1,388,0007,851,00014,487,000
TOTAL LIABILITIES AND EQUITY:5,747,0007,872,0008,451,00013,254,00018,961,00025,791,000

Income Statement (P&L) (USD)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
Operating expenses(5,449,000)(5,151,000)(4,915,000)(6,841,000)(7,591,000)(5,475,000)
Operating loss:(5,449,000)(5,151,000)(4,915,000)(6,841,000)(7,591,000)(5,475,000)
Loss from continuing operations before equity method investments, income taxes:(5,449,000)(5,151,000)(4,915,000)(6,841,000)(7,591,000)(5,475,000)
Other undisclosed income from continuing operations before income taxes   545,000   
Loss from continuing operations:(5,449,000)(5,151,000)(4,370,000)(6,841,000)(7,591,000)(5,475,000)
Loss before gain (loss) on sale of properties:(6,841,000)(7,591,000)(5,475,000)
Other undisclosed net income (loss)120,00092,000(648,000)(17,000)550,000115,000
Net loss available to common stockholders, diluted:(5,329,000)(5,059,000)(5,018,000)(6,858,000)(7,041,000)(5,360,000)

Comprehensive Income (USD)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
Net loss:(5,329,000)(5,059,000)(5,018,000)(6,858,000)(7,041,000)(5,360,000)
Comprehensive loss, net of tax, attributable to parent:(5,329,000)(5,059,000)(5,018,000)(6,858,000)(7,041,000)(5,360,000)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: